- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy ; volume:4 ; number:1 ; day:16 ; month:8 ; year:2016 ; pages:1-11 ; date:12.2016
Journal for ImmunoTherapy of Cancer ; 4, Heft 1 (16.8.2016), 1-11, 12.2016
- Creator
-
Heinzerling, Lucie
- Contributor
-
Ott, Patrick A.
Hodi, F. Stephen
Husain, Aliya N.
Tajmir-Riahi, Azadeh
Tawbi, Hussein
Pauschinger, Matthias
Gajewski, Thomas F.
Lipson, Evan J.
Luke, Jason J.
SpringerLink (Online service)
- DOI
-
10.1186/s40425-016-0152-y
- URN
-
urn:nbn:de:1111-201609011020
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Heinzerling, Lucie
- Ott, Patrick A.
- Hodi, F. Stephen
- Husain, Aliya N.
- Tajmir-Riahi, Azadeh
- Tawbi, Hussein
- Pauschinger, Matthias
- Gajewski, Thomas F.
- Lipson, Evan J.
- Luke, Jason J.
- SpringerLink (Online service)
Other Objects (12)
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Minimal change disease associated with anti-PD1 immunotherapy: a case report
Cardiovascular Magnetic Resonance Assessment of Immunotherapy Cardiotoxicity
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Normalization cancer immunotherapy: blocking Siglec-15!
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma
Rod-shaped mesoporous silica nanoparticles reduce bufalin cardiotoxicity and inhibit colon cancer by blocking lipophagy
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Minimal change disease associated with anti-PD1 immunotherapy: a case report
Cardiovascular Magnetic Resonance Assessment of Immunotherapy Cardiotoxicity
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Normalization cancer immunotherapy: blocking Siglec-15!
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma
Rod-shaped mesoporous silica nanoparticles reduce bufalin cardiotoxicity and inhibit colon cancer by blocking lipophagy
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Minimal change disease associated with anti-PD1 immunotherapy: a case report
Cardiovascular Magnetic Resonance Assessment of Immunotherapy Cardiotoxicity
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Normalization cancer immunotherapy: blocking Siglec-15!
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma
Rod-shaped mesoporous silica nanoparticles reduce bufalin cardiotoxicity and inhibit colon cancer by blocking lipophagy
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy